Americas
10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.
6 November 2025
6 November 2025
3 November 2025
Latest Features
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones.
Americas
Brazil’s updated regulations for its flagship partnerships programme marks a renewed effort to strengthen the nation's health sector, says Rob Rodrigues of RNA Law.
Americas
An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares.
Americas
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos.
Americas
If the right steps are taken, the US International Trade Commission is an attractive option for firms fearing the loss of their valuable IP, say Mary Prendergast, Mark Whitaker and Nicole Ang of Morrison Foerster.
Americas
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
More News
1 November 2025 In his first public remarks since becoming the USPTO director, a bombastic John Squires promises an agency “in overdrive” that's doubling down on AI, reports Sarah Speight.
31 October 2025 Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.
30 October 2025 Private practitioners, in-house counsel and IP services from around the world converge in the US capital for the major event, from where Sarah Speight provides on-the-ground coverage.
29 October 2025 With fraudsters exploiting new technologies, the company’s Kenya Williams explains why vigilant enforcement is money well spent to maintain a ‘clean’ brand.
28 October 2025 The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the table, finds Muireann Bolger.
27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
24 October 2025 A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox